KSEZ 10-K Annual Report Dec. 31, 2024 | Alphaminr

KSEZ 10-K Fiscal year ended Dec. 31, 2024

TABLE OF CONTENTS
Part IprintItem 1. Description Of BusinessprintItem 1A. Risk FactorsprintItem 1B. Unresolved Staff CommentsprintItem 1C. CybersecurityprintItem 2. PropertiesprintItem 3. Legal ProceedingsprintItem 4. Mine Safety DisclosuresprintPart IIprintItem 5. Market For Common Equity and Related Stockholder MattersprintItem 6. Selected Financial DataprintItem 7. Management S Discussion and Analysis Of Financial Condition and Result Of OperationsprintItem 7A. Quantitative and Qualitative Disclosures About Market RiskprintItem 8. Financial Statements and Supplementary DataprintNote 1 Organization and Description Of BusinessprintNote 2 Summary Of Significant Accounting PoliciesprintNote 3 Going ConcernprintNote 4 Accrued LiabilitiesprintNote 5 Related Party TransactionsprintNote 6 EquityprintNote 7 Notes PayableprintNote 8 LeasesprintNote 9 Subsequent EventsprintItem 9. Changes in and Disagreements with Accountants on Accounting and Financial DisclosureprintItem 9A. Controls and ProceduresprintItem 9B. Other InformationprintItem 9C. Disclosure Regarding Foreign Jurisdictions That Prevent InspectionsprintPart IIIprintItem 10. Directors, Executive Officers and Corporate GovernanceprintItem 11. Executive CompensationprintItem 12. Security Ownership Of Certain Beneficial Owners and Management and Related Stockholder MattersprintItem 13. Certain Relationships and Related Transactions, and Director IndependenceprintItem 14. Principal Accountant Fees and ServicesprintPart IVprintItem 15. Exhibits and Financial Statement Schedulesprint

Exhibits

2.1 Statement of Merger of Oncology Med Inc. filed January 5, 2015 Form 10 September 19, 2022 000-56478 3.1 Articles of Incorporation Onco Merger Sub Inc. filed January 3, 2015 Form 10 September 19, 2022 000-56478 3.2 Amendment to Articles of Incorporation of ONCO Merger Sub, Inc. filed January 18, 2015 Form 10 September 19, 2022 000-56478 3.3 Amendment to Articles of Incorporation of Oncology Med Inc. filed September 16, 2016 Form 10-K April 10, 2024 000-56478 3.4 Amendment to Articles of Incorporation filed January 20, 2017 Form 10 September 19, 2022 000-56478 3.5 Amended and Restated Articles of Incorporation dated September 12, 2022 Form 10 September 19, 2022 000-56478 3.6 Articles of Amendment to Articles of Incorporation filed February 24, 2023 Form 10-K April 10, 2024 000-56478 3.7 Articles of Amendment to Articles of Incorporation filed May 9, 2023 Form 10-K April 10, 2024 000-56478 3.8 Articles of Amendment to Articles of Incorporation filed May 9, 2023 Form 10-K April 10, 2024 000-56478 3.9 Articles of Amendment to Articles of Incorporation filed January 19, 2024 Form 8-K March 6, 2024 000-56478 3.10 By-laws of Bellatora, Inc. Form 10 September 19, 2022 000-56478 4.1 Form of Class A Warrant Certificate Form 10-K April 10, 2024 000-56478 4.2 Form of Class B Warrant Certificate Form 10-K April 10, 2024 000-56478 10.1 Promissory Note Agreement Between Coral Investment Partners, LP and Bellatora, Inc. dated June 18, 2021 Form 10 September 19, 2022 000-56478 10.2 Promissory Note Addendum 1, Debt Agreement Modification between Coral Investment Partners, LP and Bellatora, Inc. dated December 14, 2023 Form 8-K March 6, 2024 000-56478 14 Code of Ethics Form 10-K April 10, 2024 000-56478 23.1 Auditor Consent 31.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to Securities Exchange Act of 1934 Rule 13a-14(a) or 15d-14(a) 32.1 Certifications pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002